Presented by Dr. Brecher at the 40th Annual Symposium "Diagnostic and Clinical Challenges of 20th Century Microbes", held on Nov 18, 2010 in Philadelphia.
Escort Service Call Girls In Sarita Vihar,, 99530°56974 Delhi NCR
Overview of Clostridium Difficile Infections (CDI
1. Overview of Clostridium Difficile Infections (CDI) Stephen M. Brecher Ph.D. VA Boston HealthCare System BU School of Medicine
2. The opinions expressed in this presentation are those of the presenter and do not necessarily represent the views of the Veterans Affairs Health- Care System
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13. Pathogenesis of CDI Asymptomatic C. difficile colonization C. difficile exposure Antimicrobial C. difficile infection Hospitalization From Johnson S, Gerding DN. Clin Infect Dis. 1998;26:1027-1036; with permission.
14.
15.
16. In Vitro Production of Toxins in Epidemic Strain From Warny M, et al. Lancet . 2005;366:1079-1084; with permission.
17.
18.
19.
20.
21. Laboratory Diagnosis of CDI Laboratory Diagnosis Enzyme Immunoassay (EIA) Glutamate Dehydrogenase (GDH) Cell Culture Neutralization Assay (CCNA) Toxigenic Culture (Culture and CCNA) Molecular Based (PCR Or LAMP) Stool Culture
24. Cell Culture Neutralization Assay Performance Revisited * Compared to toxigenic culture. + Compared to clinical case definition and multiple test methods. Slide provided by Dr. Karen Carroll Study Method Sensitivity (%) Specificity (%) Eastwood, et al. JCM 2009; 47:3211 In house Vero cell assay* 86.4 99.2 Barbut, et al. JCM 2009;47:1276 In house MRC-5 cells* 75.8 100 Stamper, et al JCM 2009;47:373 TechLab TOX-B test* 67.2 99.1 Peterson, et al. CID 2007;45:1152 In house MRC-5 cells + 76.7 97.1
25.
26.
27.
28.
29. BD GeneOhm™ Cdiff Assay Procedure Overview Definitive On-screen Results Results in <2 Hours Stool Specimen Slide courtesy BD GeneOhm lideS provide Specimen Preparation Lysis - DNA Extraction Reconstitution Of Reagents Real-time PCR Analysis on the SmartCycler ®
30. pro GASTRO ™ Cd Workflow Specimens Clarified Stool 110 µl of nucleic acid for analysis Add buffer, Vortex & spin Slide courtesy Gen-Probe Dilute Internal Control. Combine 20 µl clarified stool and 10 µl Internal Control Run Lysis, Add Beads Perform extraction and elute in 110 µl
31. pro GASTRO ™ Cd Workflow Hands-on Time = 57 min Hands-off Time = 137 min TOTAL TIME = 194 min Slide courtesy Gen-Probe Extracted nucleic acid Prepare controls Combine 5 µl of nucleic acid & 20 µl of Mastermix in reaction tube Insert each reaction tube in SmartCycler Program instrument and run assay Mastermix
32. Xpert ® C. difficile PCR Test for Clostridium difficile Toxin B Only Results in an early as 30 minutes; assay complete in 45 minutes If negative
33.
34.
35. Summary of C. difficile PCR Published Data Slide courtesy of Dr. Susan Novak-Weekley Publication PCR Assay Sens/Spec Terhes, 2009 BD vs. Tox Culture* 96%/99% Not all negatives specimens tested by culture*. Stamper, 2009 BD vs. Tox Culture 83.6%/98.2% Eastwood, 2009 BD vs. CCCN BD vs. Tox Culture 92.2%/94% 88.5%/95.4% Kvach, 2010 BD vs. Tox Culture* 91.4%/100% Not all negatives specimens tested by culture*. Stamper, 2009 Prodesse vs. Tox Culture 77.3%/99.2% Huang, 2009 Cepheid Xpert vs. CCCN 97.1%/93.9% Novak-Weekley, 2010 Cepheid Xpert vs. Tox Culture 94.4%/96.3% Swindells, 2010 Cepheid Xpert vs Tox Culture BD vs Tox culture 100%/99.2% 94.4%/99.2%, Small “N”
36.
37.
38.
39.
40.
41.
42.
43.
Editor's Notes
Slide Originally, it was thought that the administration of antimicrobial therapy following asymptomatic colonization resulted in C. difficile -associated diarrhea. However, later findings suggested that patients who are colonized with C. difficile are at a reduced risk of developing active infection. 1 Those data led to the revised hypothesis of C. difficile pathogenesis, as shown in this slide. After hospitalization or admission to a long-term healthcare facility, patients are at an increased risk of exposure to C. difficile. The administration of antimicrobials or other agents that may alter the colonic flora (eg, chemotherapy) render the patient susceptible and lead to the development of C. difficile disease, asymptomatic C. difficile colonization, or nothing. The incubation period after exposure in a susceptible patient is less than 1 week. 1 Do not exclude the diagnosis of C. difficile in patients who have received other agents that can potentially alter the colonic flora. (This is the exception; the vast majority of patients with CDI will have received antimicrobials.) Johnson S, Gerding DN. Clostridium difficile -associated diarrhea. Clin Infect Dis. 1998;26:1027-1036.
Slide The CDC has reported a new strain of C. difficile . 3 Various methods of classification exist for the epidemic strain. The epidemic strain is characterized as toxinotype III, North American pulsed-field gel electrophoresis (PFGE) type 1, and polymerase chain reaction (PCR)-ribotype 027 (NAP1/027). 1 In Quebec, the strain is classified as Pulsovar A and was determined to be identical to NAP1. 2 This new strain produces both toxin A and toxin B and they are not “missed” by laboratories that use toxin A immunoassays. This strain has caused multiple recent outbreaks of C. difficile infection across the United States and in Montreal, Canada, and the United Kingdom. Other features of the new strain include high-level resistance to fluoroquinolones, which may be related to increased virulence. 2,4 The epidemic strain also produces binary toxin. However, the significance of binary toxin is unknown at this time. This strain appears to produce greater amounts of toxins A and B and has a deletion in the tcdC gene, which potentially downregulates toxin production. 1 This slide shows the polymorphisms and deletions in the tcdC variants that have been identified in toxinotype III strains (the tcdC protein may downregulate the production of toxins A and B), which may result in a decreased ability to regulate toxin production, causing dramatically increased amounts of toxins A and B. This association requires further verification. 4-6 Warny M, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet . 2005;366:1079-1084. Hubert B, et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile -associated disease in Quebec. Clin Infect Dis. 2007;44:238-244. CDC. Frequently asked questions about a new strain of Clostridium difficile. Fact Sheet, July 2005. McDonald LC, et al. An epidemic, toxin gene-variant strain of Clostridium difficile . N Engl J Med. 2005;353:2433-2441. Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol . 2002;40:3470-3475. Rupnik M, et al. Revised nomenclature of Clostridium difficile toxins and associated genes. J Med Microbiol. 2005;54:113-117.
Slide The figure depicts the in vitro production of toxins A and B by C. difficile isolates of toxinotype 0 (red line) and toxinotype III (blue line). These data are based on observations published recently by Warny and colleagues using isolates from 124 patients with CDAD in Quebec, Canada. Additional isolates from recent outbreaks were obtained from the US Centers for Disease Control and Prevention, Montreal, and the United Kingdom. As shown, the peak concentration of toxin A was 16 times higher in the toxinotype III strain than in type 0 strains, and the concentration of toxin B was 23 times higher. Furthermore, control strains (type 0) produced toxin during the stationary phase, whereas type III strains produced toxin during the log and stationary phases. 1 Warny M, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet . 2005;366:1079-1084.
Swindell et al paper Xpert = 19 Pos, BDGO = 18 Pos